P ϭ 0.08 vs. control (100%)]. Treatment with interleukin-1␤ induced 11␤HSD1 activity and expression in sc and omental ASC in a timeand dose-dependent manner. 15-Deoxy-⌬12,14-PGJ2, the putative endogenous ligand of the orphan nuclear receptor peroxisome proliferator-␥, significantly increased 11␤HSD1 activity in omental cells [179.7 Ϯ 29.6% (1 M); P Ͻ 0.05 vs. control (100%)] and sc [185.3 Ϯ 12.6% (1 M); P Ͻ 0.01 vs. control (100%)] ASC, and it is possible that expression of this ligand may ensure continued cortisol generation to permit adipocyte differentiation. Protease inhibitors used in the treatment of human immunodeficiency virus infection are known to cause a lipodystrophic syndrome and central obesity, but saquinavir, indinavir, and neflinavir caused a dose-dependent inhibition of 11␤HSD1 activity in primary cultures of human omental ASC.
11␤HSD1 expression is increased in human adipose tissue by TNF␣, interleukin-1␤, leptin, and orphan nuclear receptor peroxisome proliferator-␥ agonists, but is inhibited by IGF-I. This autocrine and/or paracrine regulation is tissue specific and explains recent clinical data and animal studies evaluating cortisol metabolism in obesity. Tissue-specific 11␤HSD1 regulation offers the potential for selective enzyme inhibition within adipose tissue as a novel therapy for visceral obesity. (Endocrinology 142: [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] 2001) T HE INCIDENCE OF obesity has increased dramatically throughout the world, most notably over the last 2 decades (1, 2). In the United States nearly 30% of the population have a body mass index greater than 30 kg/m 2 , whereas in the United Kingdom the figure approaches 20% (1) . Obesity is associated with considerable health risks. Although the incidences of hypertension, coronary artery disease, and diabetes mellitus increase with increasing body mass index, it is central obesity that carries by far the worst prognosis in terms of cardiovascular risk profile and sudden death (3, 4) . The mechanisms that underpin the pathogenesis of obesity remain unclear. Patients with glucocorticoid excess develop florid, but reversible, central obesity. We have previously demonstrated the presence of the enzyme 11␤-hydroxysteroid dehydrogenase type 1 (11␤HSD1) within adipose tissue (5) . In vivo, this enzyme acts as a reductase, generating active glucocorticoid, cortisol, from inactive cortisone at a prereceptor level. We have hypothesized that the enhanced expression of 11␤HSD1 within adipose tissue may be a critical component in the pathogenesis of obesity. However, clinical studies carried out in obese subjects demonstrate global inhibition of 11␤HSD1 activity as measured by urinary cortisol and cortisone metabolites and cortisone day profiles (6) . These clinical measures are believed to most accurately reflect hepatic 11␤HSD1 activity, and it is possible that tissue-specific differential regulation may be a critical component of the pathogenesis of obesity. Such a concept is supported by animal studies in which enhanced 11␤HSD1 expression has been reported in adipose tissue from obese Zucker rats, but hepatic levels were reduced (7) . We used primary cultures of human hepatocytes and adipose stromal cells (ASC) to determine whether growth factors and cyto-kines [including insulin-like growth factor I (IGF-I), tumor necrosis factor-␣ (TNF␣), and leptin] produced locally by mature adipocytes may differentially regulate 11␤HSD1.
As adipocytes mature and differentiate, expression of the orphan nuclear receptor peroxisome proliferator-␥ (PPAR␥) increases (8) . Although still debated, it is likely that 15 deoxy-⌬12,14-prostaglandin J2 (15D-PGJ2) represents the endogenous ligand to this receptor (9, 10) . To assess whether the known effects of this agent on adipocyte development could be mediated at least in part through cortisol metabolism, we treated cultures of omental and sc ASC with 15D-PGJ2 and determined its effect on 11␤HSD1 activity.
Within adipose tissue, modulation of 11␤HSD1 may well explain the observed side-effects of many pharmaceutical agents. Notably, patients with human immunodeficiency virus infection treated with protease inhibitors develop a lipodystrophic syndrome characterized by central adiposity and peripheral fat loss (11, 12) . Although these drugs may have potent effects on adipocyte development and metabolism, it is interesting to hypothesize that some of their effects may be mediated through dysregulation of cortisol metabolism within adipose tissue. We therefore determined the effects of three protease inhibitors (saquinavir, indinavir, and neflinavir) on 11␤HSD1 activity in ASC.
Materials and Methods

Primary cultures of human adipose stromal cells
The study had the approval of the local ethical committee. ASC were isolated from patients undergoing elective abdominal surgery as previously reported (5, 13). Briefly, omental or sc adipose tissue was washed in PBS containing 50,000 U penicillin and 50,000 g streptomycin (Life Technologies, Inc., Paisley, UK). The tissue was then prepared and digested with collagenase class 1 (2 mg/ml; Worthington Biochemical Corp., Reading, UK) in 1 ϫ HBSS (Life Technologies, Inc.) for 45 min at 37 C. After centrifugation at 90 ϫ g for 5 min, the pellet containing stromal cells was removed, and cells were washed with DMEM/nutrient mixture F-12 (Life Technologies, Inc.) containing 15% FCS (Life Technologies, Inc.) and seeded on 12-well plates (Corning Costar Corp., Cambridge, MA). Cells were left overnight and washed the following day with 1 ϫ HBSS and then cultured in DMEM/F-12 medium containing 15% FCS and 100 nm cortisol. At confluence medium was changed to serum-and phenol red-free DMEM/F-12 containing transferrin (10 g/ml; Sigma, Poole, UK) for 24 h before treatment.
Cells were treated for 8 -48 h with IGF-I (Sigma; 10 -100 ng/ml), GH (Sigma; 10 -100 ng/ml), TNF␣ (Sigma; 0.01-10 ng/ml), interleukin-1␤ (IL-1␤; PeproTech, London, UK; 0.01-10 ng/ml), IL-6 (PeproTech; 1-10 ng/ml), or 15D-PGJ2 (Calbiochem-Novabiochem, Darmstadt, Germany; 1-10 m) or for 24 h with indinavir (Crixivan, Merck & Co., Inc., Whitehouse Station, NJ; 1-10 m), neflinavir (Viracept, Agouron Pharmaceuticals, Inc., La Jolla, CA; 1-10 m), or saquinavir (Invirase, Roche, Mannheim, Germany; 1-10 m).
Primary cultures of human hepatocytes
Primary cultures of human hepatocytes were established as described previously (14) . Briefly, cells were isolated via a two-step collagenase perfusion, and viability was assessed by trypan blue staining. In some preparations Percoll gradients were used to improve viability. Cells were plated onto six-well, rat tail collagen-coated dishes at a density of 2.5-3.0 ϫ 10 5 /ml in DMEM with 10% FBS for 2 h. Subsequently, cells were washed with PBS, and medium was changed to Williams E medium (Life Technologies, Inc.) supplemented with insulin (20 ng/ml) and cortisol (100 nm). After 24 h cells were treated with leptin, TNF␣, IGF-I, and GH as described above for a period of 48 h. Specific enzyme assays for 11␤HSD1 activity and RNA extraction were then performed.
Stable transfected fetal kidney cells
293 cells (devoid of endogenous 11␤HSD) were transfected with either human 11␤HSD type 1 complementary DNA (cDNA; 293T1) or type 2 cDNA (293T2) as previously reported (15) and grown in MEM with 10% FBS and Geneticin (Life Technologies, Inc.) until confluence, at which point they were trypsinized using 0.125% trypsin (Life Technologies, Inc.) in 1 mm EDTA in PBS and plated on 12-well plates. The medium was then changed 24 h before treatment to serum-and phenolfree DMEM (Life Technologies, Inc.) containing 1% MEM nonessential amino acids (Life Technologies, Inc.) and 2 mm glutamine (Life Technologies, Inc.). Cells were then treated as described above.
3T3-L1
The mouse fibroblast 3T3-L1 cell line represents an in vitro adipocyte model and is known to express 11␤HSD1 (16) . Under basal conditions before confluence these cells resemble preadipocytes. Postconfluence in defined medium they differentiate into mature adipocytes. Cells were cultured until confluence in DMEM containing 10% FBS, 1% MEM nonessential amino acids, and 2 mm glutamine. Once confluent they were trypsinized (0.125%) and plated in 12-well plates until confluence, then the medium was changed to serum-and phenol red-free DMEM for 24 h before treatments.
11␤HSD assay
Assays for 11␤HSD activity were performed by incubating intact cells with 250 nm cortisone (hepatocyte, omental, and sc ASC and 293T1), 50 nm cortisol (293T2 cells), or 250 nm 11-dehydocorticosterone (3T3-L1) with appropriate tritiated tracer for 1-5 h to ensure first order kinetics in each case. After incubation, steroids were extracted using dichloromethane, separated using a mobile phase consisting of ethanol and chloroform (8:92) by TLC, and scanned using a Bioscan, Inc., 3000 image analyzer (Lablogic, Sheffield, UK). Protein levels were assayed using a commercially available kit (Bio-Rad Laboratories, Inc., Hercules, CA), and activity was expressed as picomoles of product per mg protein/h. Activity levels are presented as the percent change from the control value Ϯ se. All experiments were carried out on at least three separate occasions in triplicate. Statistical analysis was performed using one-way ANOVA on activity values corrected to the percentchange from control.
RNA extraction and RT
Total RNA was extracted using a single step extraction method (RNAzol B, AMS Biotechnology, Whitney, UK). RNA integrity was assessed by electrophoresis on 1% agarose gels, and quantity was determined spectrophotometrically at OD 260 . One microgram of total RNA was initially denatured by heating to 70 C for 5 min 30 U avian myeloblastososis virus, 200 ng random primers, 20 U ribonuclease inhibitor, and 40 nmol deoxy-NTPs with 5 ϫ reaction buffer added to the RNA and the reverse transcriptase reaction carried out at 37 C for 1 h. The reaction was terminated by heating the cDNA to 95 C for 5 min.
Analysis of 11␤HSD1 and TNF␣ receptor (p60) messenger RNA (mRNA) expression
The RT reaction was carried out as described above. PCR amplification of cDNA was performed in a one-tube multiprimer reaction using 18S ribosomal RNA (rRNA; 18S rRNA) as an internal control. Linear amplification of 18S rRNA was ensured by using 18S PCR competimers at a ratio of 2:8 (primer:competimer). Amplification for 11␤HSD1 used primers and conditions described previously (13) . Amplification of TNF␣ receptor (p60) used the following conditions and primer sequences for 36 cycles: denaturation at 94 C, annealing at 60 C, and extension at 72 C, sense primer sequence TGA GGC ATG TCA CCA CAA GT, and antisense primer sequence GAG AAG GTG GCG CAG ATT AG, yielding a specific product length of 319 bp.
Results
Treatment of primary cultures of ASC with TNF␣ resulted in a dose-dependent increase in 11␤HSD1 activity. In omen-tal ASC, activity increased to 170 Ϯ 23% (TNF␣, 1 ng/ml) and 376 Ϯ 57% [TNF␣, 10 ng/ml; P Ͻ 0.01 vs. control (100%)]. Similar changes were observed in sc ASC [590 Ϯ 271% (TNF␣, 1 ng/ml), P Ͻ 0.05; 1743 Ϯ 1015% (TNF␣, 10 ng/ml), P Ͻ 0.05; Fig. 1A ]. However, in primary cultures of human hepatocytes TNF␣ had no effect on 11␤HSD1 oxo-reductase activity [97 Ϯ 10% (TNF␣, 1 ng/ml) and 90 Ϯ 3% (TNF␣, 10 ng/ml); Fig. 1A] . Similarly, treatment with IL-1␤ caused a significant induction of 11␤HSD1 activity in both omental and sc ASC [omental, 397 Ϯ 47% (IL-1, 1 ng/ml; P Ͻ 0.01) and 415 Ϯ 71% (IL-1, 10 ng/ml; P Ͻ 0.01); sc, 416 Ϯ 71% (IL-1, 1 ng/ml; P Ͻ 0.01) and 388 Ϯ 62% (IL-1, 10 ng/ml; P Ͻ 0.01)]. Changes in enzyme activity were paralleled by changes in enzyme expression, as demonstrated by semiquantitative RT-PCR using 18S as an internal control (Fig. 1B) . TNF␣ receptor type 1 (p60) was expressed in both primary cultures of human hepatocytes and ASC, but did not appear to be regulated at the mRNA level by treatment with TNF␣ (Fig. 1B) The response to TNF␣ and IL-1 treatment in sc ASC was dependent not only upon the dose but also upon the duration of incubation (Fig. 2, A and B) . At the highest doses of TNF␣ and IL-1␤ used, induction of 11␤HSD1 activity continued to rise with increasing duration of treatment [TNF␣ (10 ng/ml), 105 Ϯ 11 pmol/mg⅐h (24 h
In sc ASC, treatment with IL-6 caused a significant increase in 11␤HSD1 activity at a dose of 1 ng/ml (174.8 Ϯ 4%; P Ͻ 0.05), although this was not observed at a dose of 10 ng/ml (167 Ϯ 101%; P Ͼ 0.5). Treatment with IGF-I in omental and sc ASC significantly reduced 11␤HSD1 activity [omental, 89 Ϯ 5% (IGF-I, 10 ng/ml) and 72 Ϯ 8 (IGF-I, 100 ng/ml; P Ͻ 0.01); sc, 62 Ϯ 17% (IGF-I, 10 ng/ml) and 50 Ϯ 15% (IGF-I, 100 ng/ml; P Ͻ 0.05)]. In cultures of human hepatocytes, IGF-I was without effect [104 Ϯ 18% (IGF-I, 10 ng/ml) and 102 Ϯ 16% (IGF-I, 100 ng/ml); Fig. 3A] . Similarly, GH failed to regulate 11␤HSD1 activity in hepatocytes [102 Ϯ 26% (GH, 10 ng/ml) and 108 Ϯ 29% (GH, 100 ng/ml)], but in ASC, GH caused a small, but significant, inhibition in activity at both sc and omental sites [omental, 77 Ϯ 9% (GH, 10 ng/ml; P Ͻ 0.05 vs. control) and 80 Ϯ 5% (GH, 100 ng/ml; P Ͻ 0.05 vs. control); sc, 71 Ϯ 8% (GH, 10 ng/ml; P Ͻ 0.05) and 78 Ϯ 8% (GH, 100 ng/ml; P ϭ 0.05)]. Treatment with leptin had no effect on 11␤HSD1 activity in hepatocytes [103 Ϯ19% (leptin, 10 ng/ml) and 92 Ϯ 11% (leptin, 100 ng/ml)]. However, in omental, but not sc, ASC, treatment with leptin caused a borderline significant increase in 11␤HSD1 activity [omental, 111 Ϯ 13% (leptin, 10 ng/ml) and 136 Ϯ 14% (leptin, 100 ng/ml; P ϭ 0.08); sc, 80 Ϯ 20% (leptin, 10 ng/ml) and 91 Ϯ 17% (leptin, 100 ng/ml); A summary of absolute activity data is presented in Table 1 .
Discussion
Glucocorticoids have many potent effects on adipose tissue. This is exemplified in patients with Cushing's syndrome, who develop a florid, but reversible, central obesity as a consequence of cortisol excess. Although patients with obesity do have abnormalities of function of the hypothalamo-pituitary-adrenal axis, their circulating cortisol levels are normal (17) , suggesting deranged cortisol metabolism. We have previously demonstrated the presence of 11␤HSD1 (but absent 11␤HSD2) in adipose tissue, with higher activity in omental ASC compared with sc cells (5) , and have hypothesized that this depot-specific activation of cortisol via 11␤HSD1 may be important in the pathogenesis of visceral obesity. To support this concept, inhibition of 11␤HSD1 within omental ASC prevented adipocyte differentiation (13) . The regulation of expression of 11␤HSD1 within adipose tissue, therefore, may be of importance with respect to the pathogenesis of obesity and, crucially, may provide therapeutic benefits.
Despite these in vitro data, clinical studies have suggested inhibition of 11␤HSD1 activity, as measured by urine steroid profiles and the appearance of circulating cortisol after oral cortisone acetate (6) . These measures undoubtedly reflect hepatic 11␤HSD1 activity, but it is still plausible that 11␤HSD1 expression may be increased in adipose tissue. Indeed, such a tissue-specific regulation of 11␤HSD1 expression has been shown in an animal model of obesity, the Zucker rat (7).
Mature adipocytes produce a variety of growth factors and cytokines, including IGF-I, leptin, and TNF␣, that may have powerful effects on 11␤HSD1 expression in a paracrine/ autocrine fashion. Levels of TNF␣ are elevated 2-to 3-fold in obesity and seem particularly associated with insulin resistance (18) . Previous studies have shown induction of 11␤HSD1 activity by TNF␣ in rat glomerular mesangial cells (19) and human breast preadipocytes (20) . In this study we demonstrated a dramatic enhancement of activity and expression of 11␤HSD1 in sc and omental ASC after treatment with TNF␣. Based on our earlier observations (13) , this local cortisol generation will promote adipocyte differentiation. The fold induction of 11␤HSD1 activity is far greater in sc than omental ASC. However, basal activity is significantly lower in sc ASC, and even after treatment with either TNF␣ or IL-1␤ the absolute activity of the enzyme remains higher in omental cells. This basal and stimulated differential cortisol generation between omental and sc depots may well be crucial to the development of central obesity. However, TNF␣ also has potent direct effects on developing adipocytes to inhibit differentiation and proliferation and to promote apoptosis and dedifferentiation (21) (22) (23) . It is possible that enhanced expression of 11␤HSD1 and the resulting increased local production of cortisol may serve as a regulatory feedback loop to balance these direct effects of TNF␣. This may also provide an explanation for the phenotype observed in both TNF␣ and TNF␣ receptor knockout mice. These mice appear to have a normal fat distribution (24) , although TNF␣ knockout mice eventually become leaner than controls (25) . The propensity for adipocyte differentiation that can occur due to lack of TNF␣ may be counteracted by the relative reduction in local cortisol caused by the absence of induction of 11␤HSD1.
Similarly, levels of IL-6 are elevated in obesity and fall with weight loss (26) . Induction of 11␤HSD1 activity in sc ASC by IL-6 will enhance cortisol generation and is likely to further contribute to the obese phenotype.
Leptin is a cytokine produced and secreted by mature adipocytes that is known to have potent central effects on feeding behavior and appetite. Its peripheral actions have been less extensively investigated. Circulating leptin levels are elevated in obesity, which has widely been regarded as a state of leptin resistance (27) . Incubation with leptin appeared to increase 11␤HSD1 activity in omental ASC, although this did not reach statistical significance (P ϭ 0.08). In sc ASC, leptin was without effect. It is possible that leptin may promote further adipogenesis at an autocrine level through increased generation of cortisol, again in a depotspecific fashion. However, compared with the effects of TNF␣ and IL-1␤, the effects were small.
Patients with obesity have relative GH deficiency (28); conversely, hypopituitary patients with GH deficiency are frequently obese (29, 30) . Our previous clinical studies have demonstrated inhibition of 11␤HSD1 in patients with acromegaly and increased expression in hypopituitary patients (31, 32) . In vitro studies have shown that this inhibition is most likely mediated by IGF-I (31). In this study using human primary ASC, we demonstrated a dose-dependent inhibition of 11␤HSD1 activity by IGF-I in both sc and omental ASC. IGF-I had no effect on 11␤HSD1 activity in primary cultures of human hepatocytes. The lack of response to GH/IGF-I in this hepatocyte model is intriguing. Clinical studies demonstrating regulation of 11␤HSD1 activity by GH suggest that the observed alterations in urinary steroid metabolites are mediated via hepatic 11␤HSD1 activity (31) . Furthermore, animal studies have clearly demonstrated decreased hepatic 11␤HSD1 expression in response to continuous GH infusion (33) . However, there is conflicting in vitro data suggesting that GH may either have no effect or cause an inhibition of 11␤HSD1 activity in primary cultures of rat hepatocytes (34, 35). Our study showed no effect of GH on 11␤HSD1 activity in primary cultures of human hepatocytes.
The PG derivative 15D-PGJ2 is believed to be the endogenous ligand for PPAR␥ (9, 10) . 15D-PGJ2 has been demonstrated to have potent effects to promote adipocyte development (9) , but intriguingly also to inhibit leptin production (36) . Treatment with PGJ2 increased 11␤HSD1 activity in ASC, and it is exciting to speculate that some of the effects of PPAR␥ agonists on adipocyte differentiation are mediated indirectly via glucocorticoids through this action on 11␤HSD1.
Local regulation of 11␤HSD1 may also offer an explanation for side-effects of some pharmaceutical agents and potentially may be a site for future novel therapeutic targets. Protease inhibitors used in the treatment of human immunodeficiency virus infection are known to cause a lipodystrophic syndrome characterized by proximal fat loss and central fat accumulation (11, 12, 37) . Our data indicate that these drugs potently inhibit 11␤HSD1 activity, but have no effect on 11␤HSD2. On the basis of these results, it would appear that local enhanced activity and expression of 11␤HSD1 do not explain the central obesity observed in patients taking protease inhibitors. The lipodystrophic syndrome is likely to result from many complex interactions during adipocyte metabolism and development. Recent studies have shown that these agents are capable of inhibiting the generation of metabolites of retinoic acid through inhibition of cytoplasmic retinoic acid-binding protein type 1 (38) . This inhibition may well influence activation and heterodimerization of the retinoid X and PPAR␥ receptors, resulting in dysregulation of adipocyte development. Effects on lipoprotein-related protein have also been described that have been implicated in the circulating dyslipidemia associated with this condition. The etiology of the lipodystrophic syndrome associated with protease inhibitors is undoubtedly complex and the role of 11␤HSD1 inhibition in this mechanism remains to be determined.
We have demonstrated the differential regulation of 11␤HSD1 in ASC and hepatocytes by IGF-I, TNF␣, and leptin, data that may help to explain existing clinical data. The local up-regulation of 11␤HSD1 within adipose tissue in the setting of inhibition in the liver documented in obesity (6) and in an animal model, the Zucker rat (7), has been described. Obesity is characterized by low GH secretion, lower IGF-I levels, and elevated levels of TNF␣ and leptin, factors that would specifically increase 11␤HSD1 within adipose tissue, but not liver. Furthermore, expression of the endogenous ligand to PPAR␥ and IL-6 may further enhance local cortisol generation. The relative contributions of all of these factors to the enhanced activity and expression of 11␤HSD1 is perhaps difficult to assess. TNF␣ and IL-1␤ have profound Values are picomoles of product formed (E, F, or B) per mg total protein/h. Shown are the mean Ϯ SE for three to six experiments performed in triplicate.
effects, whereas 15D-PGJ2, IL-6, and leptin enhance activity to a lesser degree. The mechanism by which TNF␣, leptin, and IGF-I mediate differential regulation needs further investigation. TNF␣, acting through the p60 receptor, signals either via mitogen-activated protein kinase and nuclear factor-␤ or through activator protein-1 (39) . Activator protein-1 transcription factor-binding sites have been identified in the 5Ј-promoter region of 11␤HSD1 gene (40) , and this may be the mechanism of signaling in ASC. IGF-I acts via either inositol trisphospate or mitogen-activated protein kinase. The specific intracellular pathway that is activated can have profound effects on adipocyte development to promote either proliferation or differentiation (41) . However, the precise mechanism of action of IGF-I to modulate 11␤HSD1 activity in ASC requires further investigation.
In summary, we have documented inhibition of 11␤HSD1 expression by protease inhibitors within adipose tissue, but, crucially, defined differential tissue specific regulation of 11␤HSD1 by IGF-I and TNF␣. The cytokine induction and IGF-I inhibition of 11␤HSD1 within adipose tissue provide a mechanism to explain current clinical data and have important ramifications for the pathogenesis of visceral obesity.
